Market Overview

Alexion Confirms FDA Approval For Soliris


Alexion Pharmaceuticals (NASDAQ: ALXN) has been granted approval by the Food and Drug Administration for Soliris.

Soliris (eculizumab) is an injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive.

Alexion shares traded around $126.90 at time of publication. The stock has a 52-week high of $141.86 and a 52-week low of $92.56.

Related Links:

Morphic Opens Above IPO Price

ImmunoGen To Focus Operations On Mivetuximab Soravtansine Development

Posted-In: News FDA


Related Articles (ALXN)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Analyst: Boeing 737 MAX Still On Path To Take Flight Again In 6-9 Months

Success Is Sweet For Hershey, A Shipper Of Choice